Pharma companies, drug access advocates clash over IP in USMCA trade deal
The review of the US-Mexico-Canada trade deal again has pharmaceutical companies at odds with organizations aiming to increase access to medications. IP protection requirements are at the center of a debate...To view the full article, register now.
Already a subscriber? Click here to view full article